Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy can be complicated by gastrointestinal adverse events (AEs). Similarly, gastrointestinal AEs have been reported with the use of serine/threonine-protein kinase B-Raf (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitor therapy. We i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuang, Andrew G., Mohajir, Wasay, Panneerselvam, Kavea, McQuade, Jennifer L., Oliva, Isabella C. Glitz, Khan, Muhammad Ali, Zhang, Hao Chi, Thomas, Anusha S., Wang, Yinghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756030/
https://www.ncbi.nlm.nih.gov/pubmed/36593813
http://dx.doi.org/10.20524/aog.2023.0762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756030/
https://www.ncbi.nlm.nih.gov/pubmed/36593813
http://dx.doi.org/10.20524/aog.2023.0762

Ejemplares similares